Skip to main content
Log in

Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The oxidative metabolism of tolbutamide was studied in 13 healthy subjects of known debrisoquine phenotype. Three were poor (PM) and ten were extensive (EM) metabolisers of debrisoquine.

The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml·min−1·kg−1, 3.4 h, and 0.17 ml·min−1. kg−1 in PM subjects and 0.22 ml·min−1·kg−1, 4.3 h and 0.15 ml·min−1·kg−1 in EM subjects. Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects. There were no statistically significant differences between EM and PM metabolisers for any of these parameters. In addition there was no correlation between the debrisoquine metabolic ratio and tolbutamide urinary metabolite recovery or plasma clearance.

These data indicate that hydroxylation of debrisoquine and tolbutamide are not catalyzed by the same enzyme.

The ratio of hydroxy- to carboxytolbutamide in our subjects, and in other recent studies, suggests that some previous publications were inaccurate and their conclusions about the genetic control of tolbutamide metabolism were incorrect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Eichelbaum M, Spannbrucker N, Steinke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Google Scholar 

  • Eichelbaum M, Bertilsson L, Sarve J, Zekoru C (1982) Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 31: 184–186

    Google Scholar 

  • Idle JR, Sloan TP, Smith RL, Wakile LA (1979) Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man. Br J Pharmacol 66: 430P-431P

    Google Scholar 

  • Jackson JIS, Bressler R (1981) Clinical Pharmacology of sulphonylurea hypoglycaemic agents: Part 1. Drugs 22: 211–245

    Google Scholar 

  • Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: Pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacology 22: 541–550

    Google Scholar 

  • Mahgoub A, Idle JR, Dring G, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    Google Scholar 

  • Miners JD, Wing LMH, Birkett DJ (1985) Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Aust NZJ Med 15: 348–349

    Google Scholar 

  • Peart GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465–471

    Google Scholar 

  • Prine Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  • Prine Evans DA (1986) Therapy. Ethnic difference in reactions to drugs and xenobiotics. Prog Clin Biol Res 214: 491–526

    Google Scholar 

  • Scott J, Poffenbarger P (1979) Pharmacokinetics of tolbutamide metabolism in humans. Diabetes 28: 41–51

    Google Scholar 

  • Shibasaki J, Konishi R, Takayoshi J, Veki T (1979) Drug absorption, metabolism and excretion IX. Some new aspects of pharmacokinetics of tolbutamide in rabbits. Chem Pharmacol Bull 21: 1754–63

    Google Scholar 

  • Thomas RC, Ikeda BJ (1966) The metabolic fate of tolbutamide in man and the rat. J Med Chem 9: 507–510

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peart, G.F., Boutagy, J. & Shenfield, G.M. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. Eur J Clin Pharmacol 33, 397–402 (1987). https://doi.org/10.1007/BF00637637

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00637637

Key words

Navigation